Obsessive-Compulsive Disorder (OCD)

Riluzole Medication Study for Treatment-Refractory OCD

Organization: 
Yale OCD Research Clinic
Principal Investigator: 
Christopher J. Pittenger, MD, PhD
Eligibility Criteria: 

Ages 18-65
Diagnosed with Obsessive-Compulsive Disorder

Contact: 
Suzanne Wasylink, (203) 974-7523 , ocd.research@yale.edu
Location: 
New Haven, CT
State: 
Connecticut
Study End Date: 
Tue, 2013-10-01

Brain Imaging Study for OCD using Positron Emission Tomography

Organization: 
Yale OCD Research Clinic
Principal Investigator: 
Christopher J. Pittenger, MD, PhD
Eligibility Criteria: 

Ages 18-65
Diagnosed with Obsessive-Compulsive Disorder

Contact: 
Suzanne Wasylink, (203) 974-7523 , ocd.research@yale.edu
Location: 
New Haven, CT
State: 
Connecticut
Study End Date: 
Thu, 2015-01-01

Biomarkers of OCD Subtypes Using Brain Imaging

A number of studies using different techniques have suggested that the neurotransmitter glutamate is present at excessive levels in at least some patients with OCD. This idea has motivated our use of glutamate-modulating drugs in OCD that has not responded to standard therapies. However, the details of how glutamate is out of balance in OCD remain unclear. Likewise, it is unclear whether glutamate dysregulation contributes to all forms of OCD or only to some subtypes.

Organization: 
Yale OCD Research Clinic
Principal Investigator: 
Christopher J. Pittenger, MD, PhD
Eligibility Criteria: 

Ages 18-65
Diagnosed with Obsessive-Compulsive Disorder

Contact: 
Suzanne Wasylink, (203) 974-7523 , ocd.research@yale.edu
Location: 
New Haven, CT
State: 
Connecticut
Study End Date: 
Sat, 2017-04-01

Novel medication strategies targeting brain mechanisms in pediatric ocd

This study aims to determine whether adding a medication called minocycline to

antidepressant treatment can help reduce symptoms of OCD. This study also aims to

learn more about the brains of children and adolescents with OCD.

 

Your child must be taking a stable dose of a serotonin reuptake inhibitor (SRI) in order to

participate in this study. During the 12 week study period, your child will continue to

Organization: 
Columbia University Medical Center/New York State Psychiatric Institute
Principal Investigator: 
Dr. Moira Rynn, M.D. and Dr. H. Blair Simpson
Eligibility Criteria: 

• 8 - 20 years

• Genders: both

• Key inclusion criteria: Primary diagnosis of OCD and currently on a stable and adequate dose of an SRI

 

Your child may be eligible to participate in this study if he/she is diagnosed with Obsessive-Compulsive Disorder.

Exclusion Criteria: 

• Lifetime diagnosis of: psychotic disorder, bipolar disorder, eating disorder, pervasive developmental disorder, mental retardation, or substance/alcohol dependence

• Current diagnosis of major depressive disorder, attention-deficit hyperactivity disorder (ADHD), Tourette’s/Tic Disorder, or substance/alcohol abuse

• Diagnosis of pediatric autoimmune neuropsychiatric disorders associated with streptococcus (PANDAS)

• Active Suicidal Ideation

• Hoarding as the primary OCD symptom

• Pregnant, nursing, or planning to become pregnant

Contact: 
Amy Rapp, (212) 543-5592.
Location: 
New York, NY
State: 
New York

New Podcast: Treating Coexisting Depression and Anxiety

10/1/2012

Listen to Dr. Dennis Greenberger describe the differences and similarities between symptoms of anxiety and depression, how the disorders are treated, and what patients can expect in treatment.

Mind Over Moods — Treating Coexisting Depression and Anxiety

ADAA

Dennis Greenberger, PhD
Founder and Director
Anxiety & Depression Center
Newport Beach, California

Assistant Clinical Professor
Department of Psychiatry
University of California, Irvine, College of Medicine

Dr. Greenberger describes the differences and similarities between symptoms of anxiety and depression, how the disorders are treated, and what patients can expect in treatment.

Listen

Attaining and Maintaining Wellness in OCD (#6628)

A research study offering treatment for people who have obsessive-compulsive disorder (OCD) and are currently taking one of the following medications and still have unwanted symptoms:

  • Clomipramine (Anafranil)
  • Fluoxetine (Prozac)
  • Fluvoxamine (Luvox)
  • Sertraline (Zoloft)
  • Paroxetine (Paxil)
  • Citalopram (Celexa)
  • Escitalopram (Lexapro)

The goal of the study is to understand whether patients with OCD on serotonin reuptake inhibitors (SRIs) who achieve wellness from EX/RP can safely discontinue their medication.

Organization: 
Center for OCD and Related Disorders at the New York State Psychiatric Institute at Columbia University; http://columbia-ocd.org/
Principal Investigator: 
H. Blair Simpson, MD, PhD
Eligibility Criteria: 

You may be eligible if

  • You have OCD.
  • You are between the ages of 18 and 75.
  • You are still having bothersome symptoms while taking one of the medications listed below for OCD.
  • You are interested in receiving no-cost therapy treatment that may improve your symptoms so that you may be able to stop taking your medication.
  • Clomipramine (Anafranil)
  • Fluoxetine (Prozac)
  • Fluvoxamine (Luvox)
  • Sertraline (Zoloft)
  • Paroxetine (Paxil)
  • Citalopram (Celexa)
  • Escitalopram (Lexapro)
Contact: 
Dr. Marcia Kimeldorf at 212-543-5462 or 212-543-5367
Location: 
1051 Riverside Drive, New York, NY 10032
State: 
New York

Neurobehavioral Tasks in OCD

A research study comparing patients with OCD to patients with several other disorders to help us understand the differences in the neurocircuitry of the brain across disorders.

This study uses different behavioral tasks and questionnaires to measure participants’ stress reactivity, startle reflexes, and preferences. All information will be kept completely confidential.

Organization: 
Anxiety Disorders Clinic, Columbia University Medical Center
Principal Investigator: 
Franklin Schneier, MD
Eligibility Criteria: 

You may be eligible if

  • OCD is your primary problem
  • you are between the ages of 18 and 50
  • you are not currently on any psychiatric medications or hormonal birth control
  • you are not pregnant

You must be able to travel to the New York State Psychiatric Institute/Columbia University at 1051 Riverside Drive (at 168th Street) in Manhattan.

 

Exclusion Criteria: 
  • You are not between the ages of 18 and 50.
  • You are currently on any psychiatric medications or hormonal birth control.
  • You are pregnant.
  • Unable to travel to the New York State Psychiatric Institute/Columbia University at 1051 Riverside Drive (at 168th Street) in Manhattan.
Contact: 
212-543-5367 or goldmar@nyspi.columbia.edu
Location: 
1051 Riverside Drive (at 168th Street) in Manhattan
State: 
New York

New Personal Story: Perfectionism and Panic

9/20/2012

A successful young woman breaks free from her "prison" of panic and OCD, thanks to her search for treatment. "So often, people who suffer from anxiety are laughed at as weak or neurotic. I’d like to think we’re actually pretty strong: It takes a lot to silently control a ping-ponging mind." Read on.

“The world was once my oyster; now, it was my prison.”

Perfectionism and Panic

Kara Baskin familyBack in 2006, I had it all: A loving fiancé, a coveted publishing job, a supportive network of friends and family. I was living in Washington, D.C., where I went out almost every night to press parties and trendy restaurants. In my spare time, I delivered meals on wheels and counseled Alzheimer’s patients at the local senior center. Perfectionistic and ever so vigilant, I could’ve won the Perfect Life Olympics.

Read

Contact ADAA

8701 Georgia Ave. #412
Silver Spring, MD 20910

240.485.1001

Contact ADAA

Request Publications

FacebookTwitterRSS

Syndicate content RSS

 

ADAA is a national nonprofit organization dedicated to the prevention, treatment, and cure of anxiety, OCD, PTSD, depression, and related disorders and to improving the lives of all people who suffer from them.

 

Health Impact Award

Award for Excellence


Independent Charities of America